Here’s why Citi says crypto prices have been weak recently
LONDON - EKF Diagnostics Holdings plc (AIM:EKF) has purchased 919,331 of its ordinary shares at 28 pence per share and announced an extension to its share buyback program with an additional allocation of approximately £1 million, according to a company press release.
The global diagnostics business reported that the purchased shares will be held in treasury. The buyback extension follows the initial program announced on May 21, 2025, and will be conducted through on-market purchases under authorities obtained at the company’s annual general meeting held on May 20, 2025.
As part of Monday’s transactions, EKF acquired 272,000 ordinary shares from Harwood, which acted as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The company purchased 90,667 shares from Oryx and 181,333 from NASCIT at 28 pence per share.
The transaction was facilitated to ensure that the aggregate indirect beneficial interest of Non-Executive Director Christopher Mills remains at approximately the same level and does not exceed 30% of the company’s total voting rights following any repurchases. Following the sale, Mills’ aggregate indirect interest in the company stands at 131,378,000 ordinary shares.
After the buyback, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 3,575,045 held in treasury. The total number of ordinary shares carrying voting rights is now 445,518,745.
EKF Diagnostics operates in the point-of-care diagnostics sector, focusing on hematology and diabetes, and provides life sciences services through five manufacturing sites across the US and Germany, selling into over 120 countries worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.